Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET.

The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/ 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260512769478/en/

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
[email protected]
Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc

You May Also Be Interested In

• Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
• CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
• Mitsubishi Electric’s New S-EIV-X Uses Remote Data to Optimize Energy Saving for Railway Operators